Clinical trial Recruiting at 1 site Observational Ages 0 Hours to 72 Hours

Using exosome microRNAs to identify metabolic bone disease in premature infants

Official title: Prospective Cohort Study of Exosomal microRNAs as Biomarkers for Diagnosis and Therapeutic Efficacy Evaluation of Metabolic Bone Diseases in Premature Infants

Run by Hunan Children's Hospital · NCT06368154 · Data updated 2026-11-12

This study is trying to see if tiny particles in the blood of premature babies can help doctors spot a serious bone disease early on.

More Newborn trials

Quick facts

Study typeObservational
Ages0 Hours to 72 Hours
SexAll
Enrollment200 (estimated)
SponsorHunan Children's Hospital
Government
Locations1 site (Changsha, Hunan)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 16, 2024
Trial IDNCT06368154 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are preterm infants aged less than 28 days with a gestational age between 37 and 41 weeks.

Probably not a fit

Patients who have undergone blood transfusions, surgeries, or have congenital malformations or inherited metabolic diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the potential of exosome microRNAs as biomarkers for metabolic bone disease of prematurity (MBDP) in preterm infants. MBDP is a serious condition characterized by insufficient calcium and phosphorus, leading to complications in bone health. The study will analyze plasma exosomes from preterm infants to identify specific microRNAs that could serve as early diagnostic markers for this condition. By focusing on infants with a gestational age of 37 to 41 weeks and under 28 days old, the research seeks to improve early detection methods for MBDP.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of metabolic bone disease in premature infants, potentially improving their health outcomes.

How similar studies have gone: Previous studies have shown promise in using plasma or serum microRNAs as molecular markers for early prediction of bone diseases, indicating a potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The gestational age was 37+0-41+6 weeks and the age was less than 28 days

Exclusion Criteria:

* There was no blood transfusion, no operation, no congenital malformation, no inherited metabolic diseases, no history of intravenous nutrition, and no intestinal diseases

Where it's running

  • Hunan Children's Hospital
    Changsha, Hunan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.